The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Two-year follow-up data of a Phase I study investigating zamtocabtagene autoleucel in R/R NHL
In this video, Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, discusses the two-year follow-up data of a Phase I study investigating the use of zamtocabtagene autoleucel (MB-CART2019.1) for the treatment of patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) (NCT03870945). This study showed that dual CD20/CD19 targeting provided major advantages in terms of efficacy and tolerability, seeing a complete remission (CR) in 5 out of 12 patients as well as no dose-limiting toxicities (DLTs). Prof. Borchmann also talks on the ongoing DALY 2-EU trial (NCT04844866), which is seeking to determine superiority of this agent compared to standard of care (SoC) therapy in patients with R/R diffuse large B-cell lymphoma (DLBCL) ineligible for high-dose chemotherapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
